Table 3.

Current Phase III clinical trials of chemovirotherapy

Name	Tumor	Patients	Combination	Route	Sequence	Study sites	Status (NCT/PMID reference)
ReO 018 (Reolysin)	Head and neck cancer	Recurrent/metastatic platinum refractory squamous cell carcinoma Patient subgroup 1: locoregional tumors with or without metastases (n=118) Patient subgroup 2: only measured distal metastases (n=47)	CBCDA + PTX	IV	Day 1: PTX 3 h, CBCDA 0.5 h Days 1–5: Reolysin daily 1 h (21 days per cycle) Control arm: CTX + IV placebo (no virus)	Multicenter US, Russia, UK, Spain, Hungary, Canada, Italy, Poland, Belgium, France, Germany, Greece, Slovenia	Completed, NCT01166542

Notes: A search for ongoing and published clinical trials was carried out on the clinical trial database http://clinicaltrials.gov/ and http://www.ncbi.nlm.nih.gov/pubmed/. Further data on the study design of the ReO 018 trial are from Oncolytics Biotech (http://www.oncolyticsbiotech.com/english/clinical-trials/clinical-trials-news/clinical-trials-details/2013/ReO-018/).

Abbreviations: CBCDA, carboplatin; CTX, chemotherapy; IV, intravenous; PTX, paclitaxel; h, hour(s); NCT, National Clinical Trial number; PMID, PubMed identifier.